NCT00073749 2018-12-17
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Pfizer
Phase 1 Completed
Clinical Trials
3 trialsNCT00299494 2018-03-08
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Pfizer
Phase 1/2 Completed
NCT00868608 2017-10-31
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Pfizer
Phase 2 Completed